Poolbeg Pharma #POLB commences trading on OTCQB Market in the United States March 30, 2022 – Posted in: Blog, Poolbeg Pharma (POLB)
30 March 2022 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical stage infectious disease pharmaceutical company with a unique capital light clinical model, announces that trading in the Company’s Ordinary Shares of nominal value of £0.02 each (“Ordinary Shares”) will commence today on the OTCQB Venture Market in the United States. The Company’s OTCQB shares will have the ticker: POLBF. There is no associated capital raise with this cross trading and Poolbeg’s…
Continue reading